BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan
Business Wire - Thu May 08, 6:30AM CDT
--- Management to host conference call today at 8:30 am ET -
BIND Therapeutics to Present at UBS Global Healthcare Conference
Business Wire - Mon May 05, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Monday, May 19, 2014 at 11:00 a.m. ET.
BIND Therapeutics to Report First Quarter 2014 Financial Results on May 8, 2014
Business Wire - Thu May 01, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced it will report first quarter 2014 financial results on Thursday, May 8, 2014. BIND's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Thursday, May 8, 2014 to discuss the quarterly results and recent business developments.
BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting
Business Wire - Mon Apr 07, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The clinical data from a completed Phase 1 study demonstrate differentiating attributes of BIND-014 administered with a weekly dosing schedule which may enable increased dose intensity and enhanced therapeutic efficacy of BIND-014. In addition, data supporting the potential utility of PSMA as a target and marker for BIND-014 patient selection were presented.
Company news for March 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 9:06AM CDT
Companies in the News are: CCL,BIND,MKC,WAG
BIND Therapeutics, Inc. [BIND] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Mar 25, 10:21AM CDT
What:
BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Mar 25, 6:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today reported financial results for the fourth quarter and year-ended December 31, 2013.
BIND Therapeutics to Ring the NASDAQ Stock Market Opening Bell on March 26, 2014
Business Wire - Wed Mar 19, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that Company management will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Wednesday, March 26, 2014. A live webcast will be available at https://new.livestream.com/nasdaq/live.
BIND Therapeutics to Report Fourth Quarter and Year End 2013 Financial Results and Business Developments on March 25, 2014
Business Wire - Tue Mar 18, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014. BIND's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time, on Tuesday, March 25, 2014 to discuss the quarterly results and recent business developments.
BIND Therapeutics to Present Data at the AACR 2014 Annual Meeting
Business Wire - Wed Mar 05, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.
BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth
Business Wire - Mon Mar 03, 3:15PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team. Andrew Hirsch has been appointed Chief Operating Officer with expanded responsibilities, including program and alliance management and oversight of BIND's Russian operations. Andrew will continue to serve as Chief Financial Officer of the company. Jeff Hrkach, Ph.D., formerly Senior Vice President, Technology Research and Development, has been promoted to Chief Technology Officer with responsibility for the research, development and manufacturing of BIND's Accurin pipeline and research and technology development related to BIND's Medicinal Nanoengineering(R) platform.
BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
BIND Therapeutics to Present at Cowen 34th Annual Healthcare Conference
Business Wire - Mon Feb 24, 8:04AM CST
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the Cowen 34th Annual Healthcare Conference in Boston on Tuesday, March 4, 2014 at 10:40 a.m. ET.
3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Concise Analysis of the Opportunities in the International Graphene Industry
M2 - Mon Feb 03, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/krkmk8/the_graphene) has announced the addition of the "Concise Analysis of the Opportunities in the International Graphene Industry" report to their offering. A decade ago when the first edition of the Nanotechnology Opportunity Report was published, there were predictions of untold riches for early investors, the replacement of all manufacturing as we know it, and the mythical trillion-dollar market. The author went against the grain by predicting that it would be hard for anyone to make money from nanomaterials, and that the real value would be in the applications. This has been borne out by the failure of even large global companies such as Mitsubishi Chemical and Bayer to make much headway with fullerenes and carbon nanotubes, and the failure of countless smaller nanomaterials producers. On the other hand companies making use of nanomaterials, Germany's Magforce Technologies and the US based BIND Therapeutics have shown what can be achieved when nanomaterials are applied to large addressable markets, in this case drug delivery. Is Graphene The New Nanotech? A similar amount of hype currently surrounds graphene, with wild predictions of applications ranging from microelectronics to water treatment. This report examines these claims and taking the rational approach for which the author is known, considers how valid these are and evaluates the chances of success. The author also looks in detail at the graphene producers. Graphene comes in a wide range of forms, each with its own particular set of addressable applications. No one producer covers all applications and many are destined to be niche players. As with nanomaterials, many companies currently producing graphene are destined to burn brightly and then be unceremoniously snuffed out when scale up or access to applications fails to materialise. Key Topics Covered: Introduction A Brief History of Carbon Nanomaterials Can Graphene Succeed Where Fullerenes Failed? Types of Graphene Large-Scale Production Applications of Graphene The Graphene Opportunity Advanced Materials Structural Composites Microelectronics Key Applications Photonics & Optoelectronics For more information visit http://www.researchandmarkets.com/research/kr...e_graphene
BIND Therapeutics to Present at February Healthcare Conferences
Business Wire - Tue Jan 28, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the following healthcare conferences during February 2014:
Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 08, 12:32PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why BIND Therapeutics Inc. Shares Soured
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 08, 11:54AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BIND Therapeutics , a clinical-stage...
BIND Therapeutics Announces Departure of Chief Medical Officer
Business Wire - Tue Jan 07, 3:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that Greg Berk, M.D., Chief Medical Officer, will be leaving BIND to pursue another opportunity. Dr. Berk will serve as an advisor to BIND after his departure.